Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Dual-Imaging catheter aims to spot dangerous heart plaques

NCT ID NCT05753085

Knowledge-focused Sponsor: Barts & The London NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study was designed to test a new catheter that takes two types of pictures inside heart arteries at the same time—using sound and light. The goal was to see if this hybrid approach is safer and better at identifying fatty plaques that could cause heart attacks compared to standard single-image methods. The study planned to enroll 50 heart attack patients but was withdrawn before any participants were recruited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Conavi Medical Novasight Hybrid System (IVUS-OCT catheter)
What this could lead to
If successful, this could lead to better identification of dangerous plaques in heart arteries and more tailored treatment for heart attack patients.
What could go wrong
This study was withdrawn before enrolling any patients, so no results are available. The approach is still experimental and may not prove superior to standard imaging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General Inclusion Criteria 1. Age ≥ 18 to ≤80 years 2. Patient has capacity and willing to consent 3. Must be able to understand English language adequately 4. Patient admitted with an NSTEMI listed for coronary angiography Angiographic Inclusion Criteria 1) Culprit lesion amenable to PCI Exclusion Criteria: General exclusion criteria: 1. eGFR \<45ml/min/1.73m², 2. No known conditions with anticipated life expectancy \<1 year, 3. History of heart transplantation, 4. History of Coronary Artery Bypass Grafts (CABG ) 5. Intravenous contrast allergy or inability to receive treatment with aspirin, heparin, or thienopyridines, 6. Pregnant or lactating women 7. Decompensated heart failure, or known left ventricular ejection fraction ≤30% Angiographic exclusion criteria: 1. TIMI 0 flow distally to the culprit lesion, 2. The culprit lesion is located in the left main stem or the ostium of the right coronary artery, 3. Patient that requires surgical revascularization, 4. Unfavourable anatomy for intravascular imaging (i.e., the culprit lesion is a chronic total occlusion or is located in a tortuous vessel where intravascular imaging is not feasible) Intraprocedural exclusion criteria: 1\) If the patient demonstrates evidence of active ischemia or hemodynamic compromise of concern to the operator prior to first insertion of the imaging device (e.g., such as a complication caused by wiring the lesion or after pre-dilating prior to advancing the imaging device for the first time) the study procedure should not commence.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction atherosclerosis coronary artery disorder coronary stenosis Plaque, Amyloid Plaque, Atherosclerotic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Coronary stenosis Plaque, atherosclerotic

Contacts and locations

Locations

  • St Bartholomew's Hospital

    London, England, EC1A 7BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.